Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DNA Editor Named Runner-up Breakthrough of 2012

Published: Wednesday, February 27, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
A discovery that allows life scientists to precisely edit genomes for everything from crop and livestock improvement to human gene and cell therapy was named runner-up for Science magazine's 2012 Breakthrough of the Year.

The work by Adam Bogdanove, Cornell professor of plant pathology and plant-microbe biology, joined eight other runners-up to Breakthrough of the Year -- the discovery of the Higgs boson -- in the magazine's Dec. 21 issue.

Bogdanove's breakthrough, which came in 2009 while he worked as a plant pathologist at Iowa State University, allows researchers to target and cut DNA in a living cell. Bogdanove identified a DNA targeting mechanism in proteins called TAL effectors that are used by plant pathogenic bacteria to alter gene expression in their hosts.

In 2010 he and collaborators at the University of Minnesota showed that these proteins could be used to carry an enzyme that cuts DNA, called a nuclease, that target specific DNA sequences in an organism's genome. The combination of TAL effector and nuclease is called a TALEN.

"The ability to cut DNA in living cells with TALENs allows researchers to modify DNA with higher efficiency than was previously possible," Bogdanove said. While another technology called zinc finger nucleases can also target specific genes, those nucleases are hard to make, and one company owns most of the patents. TALENs can be easily and cheaply constructed and are widely available.

TALENs give researchers the power not only to target and knock out specific gene sequences, but also to replace them with new DNA. The technology opens the door for medical applications such as gene therapy.

Depending on the nature of, say, a genetic defect, researchers may soon be able to extract a patient's cells, place them in a petri dish, remove the genetic mutation, replace that sequence with healthy code, and reintroduce the patient's own cells, now fixed, Bogdanove said.

Similarly, plant breeders may use TALENs to sidestep traditional breeding of crops by inserting new, site-specific genetic information, he added.

Bogdanove is working to further understand the basic biology of plant bacteria interactions with TAL effectors. "In that context, we expect to learn fundamental things of how these proteins interact with DNA that further inform technology development," he said.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Turn out the Light: 'Switch' Determines Cancer Cell Fate
Like picking a career or a movie, cells have to make decisions – and cancer results from cells making wrong decisions.
Friday, May 03, 2013
Physicists Crack Science of Ice Formation
Salt - and just about anything else that dissolves in water, which is called a solute - lowers water's melting point, which is why it's useful for de-icing roads.
Thursday, February 28, 2013
Puppy Born from Frozen Embryo Fetches Good News
Breakthrough shows hope for endangered canids.
Tuesday, February 05, 2013
Some Stem Cells Can Trigger Tumors
When in contact with even trace amounts of cancer cells, stem cells can create a microenvironment suitable for more tumors to grow.
Wednesday, June 06, 2012
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!